Responses
Rheumatoid arthritis
Original article
A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
Compose a Response to This Article
Other responses
No responses have been published for this article.